文献速递肝病消化道肿瘤与早癌

基于磷酸化蛋白质组学的筛选揭示非致癌性受体酪氨酸激酶肝脏特异性获得所驱动癌症的新药物协同作用

A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
PubMed 文献 · Hepatology · 2017-09-29

该研究通过小鼠模型证明野生型Met受体酪氨酸激酶(RTK)水平轻微升高即可诱发肝脏自发肿瘤,并将该模型与部分肝细胞癌(HCC)患者对应;利用磷酸化蛋白质组学筛选设计药物筛选,发现MEK、核糖体S6激酶和CDK1/2抑制剂与Bcl-XL抑制的合成致死协同作用,并揭示pERK+/BCL-XL+/MCL1+特征与HCC患者不良预后相关。

要点

  • 野生型Met RTK水平轻微升高足以在小鼠肝脏诱发自发肿瘤。
  • Alb-R26Met小鼠肝脏肿瘤模型对应部分HCC患者亚群。
  • MEK、S6K、CDK1/2抑制与Bcl-XL抑制在肝癌细胞中显示协同致死效应。

核心结论

  • 肝脏细胞对非致癌性RTK水平的细微变化高度易感,可获得促进完整肿瘤发生程序的分子特征。
  • 研究结果揭示了新的合成致死相互作用,作为一组HCC患者的潜在治疗策略。

研究设计与样本

  • 研究使用Alb-R26Met小鼠模型,通过遗传学方法证明野生型Met RTK水平轻微升高足以诱发肝脏自发肿瘤。
  • 分析96个基因在肿瘤样本中的表达,将Alb-R26Met小鼠肝脏肿瘤模型与HCC患者亚群对应。
  • 结合磷酸化蛋白质组学筛选与生物信息学分析阐明肿瘤发生的调控网络。
  • 基于Alb-R26Met HCC与对照肝脏的信号多样性结果设计「有根据的猜测」药物筛选,鉴定新的合成致死相互作用。
  • 在panel of liver cancer cells中验证MEK、核糖体S6激酶和CDK1/2抑制剂与Bcl-XL抑制的协同效应。

主要发现

  • 野生型Met RTK水平轻微升高足以在小鼠肝脏诱发自发肿瘤。
  • Alb-R26Met小鼠肝脏肿瘤模型对应部分HCC患者亚群,具有临床相关性。
  • MEK、核糖体S6激酶和CDK1/2抑制与Bcl-XL抑制在肝癌细胞中显示协同致死效应。
  • MEK与Bcl-XL靶向联合机制上伴随磷酸化细胞外信号调节激酶(pERK)和髓细胞白血病1(MCL1)水平的下调。
  • pERK+/BCL-XL+/MCL1+特征在Alb-R26Met肿瘤中失调,并表征预后不良的HCC患者亚组。

临床怎么用

  • 作者认为MEK、核糖体S6激酶和CDK1/2抑制与Bcl-XL抑制的合成致死相互作用可作为一组HCC患者的潜在治疗策略。
  • 作者指出pERK+/BCL-XL+/MCL1+特征可识别预后不良的HCC患者亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Genetic mutations leading to oncogenic variants of receptor tyrosine kinases (RTKs) are frequent events during tumorigenesis; however, the cellular vulnerability to nononcogenic RTK fluctuations has not been characterized. Here, we demonstrated genetically that in the liver subtle increases in wild-type Met RTK levels are sufficient for spontaneous tumors in mice (Alb-R26Met ), conceptually illustrating how the shift from physiological to pathological conditions results from slight perturbations in signaling dosage. By analyzing 96 different genes in a panel of tumor samples, we demonstrated that liver tumorigenesis modeled by Alb-R26Met mice corresponds to a subset of hepatocellular carcinoma (HCC) patients, thus establishing the clinical relevance of this HCC mouse model. We elucidated the regulatory networks underlying tumorigenesis by combining a phosphokinome screen with bioinformatics analysis. We then used the signaling diversity results obtained from Alb-R26Met HCC versus control livers to design an "educated guess" drug screen, which led to the identification of new, deleterious synthetic lethal interactions. In particular, we report synergistic effects of mitogen-activated protein kinase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combination with Bcl-XL inhibition on a panel of liver cancer cells. Focusing on mitogen-activated protein kinase kinase and Bcl-XL targeting, we mechanistically demonstrated concomitant down-regulation of phosphorylated extracellular signal-regulated kinase and myeloid cell leukemia 1 levels. Of note, a phosphorylated extracellular signal-regulated kinase+/BCL-XL+ /myeloid cell leukemia 1+ signature, deregulated in Alb-R26Met tumors, characterizes a subgroup of HCC patients with poor prognosis. CONCLUSION: Our genetic studies highlight the heightened vulnerability of liver cells to subtle changes in nononcogenic RTK levels, allowing them to acquire a molecular profile that facilitates the full tumorigenic program; furthermore, our outcomes uncover new synthetic lethal interactions as potential therapies for a cluster of HCC patients. (Hepatology 2017;66:1644-1661).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fan Y, Arechederra M, Richelme S, et al. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases. Hepatology. 2017. PMID: 28586114. doi:10.1002/hep.29304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。